AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

AngioDynamics announced two milestones for its NanoKnife System's irreversible electroporation (IRE) technology. The available article text identifies publication of results from the DIRECT study in The Oncologist as the first milestone but provides no study findings or details of the second milestone.

Analysis

The excerpt is too incomplete to underwrite a clinical or commercial inflection: it identifies publication of DIRECT study results but gives no endpoints, patient population, comparator, follow-up, safety profile, or details of the second milestone. Publication can improve clinician awareness and credibility for AngioDynamics’ NanoKnife IRE platform, but it does not by itself establish regulatory status, guideline uptake, reimbursement, or repeatable procedure growth. Those are the transmission points from clinical evidence to revenue; without them, the near-term risk is that investors capitalize visibility before utilization changes.

Over 1–3 months, verify the full paper and the other announced milestone, then monitor company commentary for procedure volumes, site adoption, reimbursement coverage, and any regulatory or guideline developments. Over 6–18 months, genuinely differentiated outcomes could shift some eligible patients from surgery or thermal ablation toward IRE, but adoption will depend on evidence quality, physician training, and hospital economics—not publication alone. The key contrarian risk is assuming that a favorable study automatically creates broad standard-of-care adoption. This is a watch item, not a demonstrated earnings catalyst; the thesis weakens if the full results show limited durability or safety concerns, or if subsequent disclosures show no adoption or coverage progress.

Key Decisions for Investors

• Do not trade the headline alone; the supplied excerpt omits the study results and the second milestone. Retrieve the paper and confirm endpoints, cohort size, comparator, follow-up, adverse events, and whether findings support a clinically meaningful advantage.
• Put ANGO on a catalyst watchlist rather than initiating a directional position. Reassess after the full evidence and milestone details are available, and look for corroboration in procedure-volume or site-adoption disclosures.
• If the evidence is strong, treat it as a potential medium-term adoption catalyst—not an immediate revenue estimate. Track reimbursement, guideline inclusion, and physician uptake; absent progress on these, clinical interest may not translate into sales.
• Falsifiers include weak or short-lived outcomes, material safety concerns, lack of reimbursement or guideline progress, and subsequent company disclosures showing no sustained utilization growth.